Ken Griffin’s New Frontier Health Corporation Warrants, each whole warrant exercisable for one Ordinary Share at a NFH.WS Stock Holding History

Ken Griffin’s Portfolio NFH.WS Stock Details NFH.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-23,760	Closed	-$66K	–	15281
2021 Q4	$66K	Buy	23,760 +2,042	+9%	+$5.89K	﹤0.01%	13089
2021 Q3	$64K	Sell	21,718 -2,078	-9%	-$6.08K	﹤0.01%	13235
2021 Q2	$66K	Sell	23,796 -2,455	-9%	-$7K	﹤0.01%	13205
2021 Q1	$77K	Sell	26,251 -4,194	-14%	-$10.1K	﹤0.01%	12672
2020 Q4	$66K	Buy	30,445 +115	+0.4%	+$228	﹤0.01%	10457
2020 Q3	$53K	Buy	30,330 +300	+1%	+$516	﹤0.01%	9585
2020 Q2	$41K	Buy	30,030 +9,086	+43%	+$11.3K	﹤0.01%	9391
2020 Q1	$20K	Buy	+20,944	New	+$25.8K	﹤0.01%	9309

Ken Griffin's NFH.WS Position: Q1 2022 in Review

Ken Griffin sold out of New Frontier Health Corporation Warrants, each whole warrant exercisable for one Ordinary Share at a (NFH.WS) in Q1 2022, closing a stake of 23,760 shares — an estimated $66K sold.

Ken Griffin first reported a position in NFH.WS in Q1 2020 and held it in 8 quarters. The position peaked at $77K in Q1 2021. 0 funds tracked by Wall St. Rank hold NFH.WS as of Q1 2022.

Ken Griffin reported no remaining New Frontier Health Corporation Warrants, each whole warrant exercisable for one Ordinary Share at a position as of Q1 2022 after selling out during the quarter.
Ken Griffin sold 23,760 New Frontier Health Corporation Warrants, each whole warrant exercisable for one Ordinary Share at a shares in Q1 2022, an estimated $66K.
Ken Griffin first reported a position in New Frontier Health Corporation Warrants, each whole warrant exercisable for one Ordinary Share at a in Q1 2020 and held it in 8 quarters.
Ken Griffin's New Frontier Health Corporation Warrants, each whole warrant exercisable for one Ordinary Share at a position peaked at $77K in Q1 2021.
0 funds tracked by Wall St. Rank held New Frontier Health Corporation Warrants, each whole warrant exercisable for one Ordinary Share at a as of Q1 2022.

Based on Citadel Advisors's 13F filing for Q1 2022, filed 16 May 2022.